ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Antibody-based targeting of alternatively spliced tissue factor: A new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma

Permanent link
https://hdl.handle.net/10037/10639
DOI
https://doi.org/10.18632/oncotarget.7955
Thumbnail
View/Open
article.pdf (5.403Mb)
publisher's pdf (PDF)
Date
2016
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Unruh, Dusten; Ünlü, Betü; Lewis, Clayton S.; Qi, Xiaoyang; Chu, Zhengtao; Sturm, Robert; Keil, Ryan; Ahmad, Syed A.; Sovershaev, Timofey; Adam, Mariette; Van Dreden, Patrick; Woodhams, Barry J.; Ramchandani, Divya; Weber, Georg F.; Rak, Janusz W.; Wolberg, Alisa S.; Mackman, Nigel; Versteeg, Henri H.; Bogdanov, Vladimir Y.
Abstract
Alternatively spliced Tissue Factor (asTF) is a secreted form of Tissue Factor (TF), the trigger of blood coagulation whose expression levels are heightened in several forms of solid cancer, including pancreatic ductal adenocarcinoma (PDAC). asTF binds to β1 integrins on PDAC cells, whereby it promotes tumor growth, metastatic spread, and monocyte recruitment to the stroma. In this study, we determined if targeting asTF in PDAC would significantly impact tumor progression. We here report that a novel inhibitory anti-asTF monoclonal antibody curtails experimental PDAC progression. Moreover, we show that tumor-derived asTF is able to promote PDAC primary growth and spread during early as well as later stages of the disease. This raises the likelihood that asTF may comprise a viable target in early- and late-stage PDAC. In addition, we show that TF expressed by host cells plays a significant role in PDAC spread. Together, our data demonstrate that targeting asTF in PDAC is a novel strategy to stem PDAC progression and spread.
Description
Published version. Source at http://doi.org/10.18632/oncotarget.7955. License CC BY 3.0.
Publisher
Impact Journals
Citation
Unruh D, Ünlü, Lewis, Qi, Chu, Sturm, Keil, Ahmad, Sovershaev TA, Adam, Van Dreden, Woodhams, Ramchandani, Weber, Rak, Wolberg, Mackman N, Versteeg HH, Bogdanov. Antibody-based targeting of alternatively spliced tissue factor: A new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. OncoTarget. 2016;7(18):25264-25275
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)